All composite outcomes were significantly greater ( Bonferroni significance level , P0 .016 ) with combination therapy ( i.e. infliximab and azathioprine ; 52.3-63 .6 % ) vs. azathioprine monotherapy ( 12.9-29 .0 % ; p 0.005 for all comparisons ) .